Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has been given an average recommendation of “Hold” by the twenty-one research firms that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $51.08.

PCRX has been the subject of a number of analyst reports. Zacks Investment Research lowered Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 9th. Canaccord Genuity reiterated a “buy” rating and set a $44.00 price target (down previously from $48.00) on shares of Pacira Pharmaceuticals in a research report on Sunday, October 1st. CIBC assumed coverage on Pacira Pharmaceuticals in a report on Thursday, September 7th. They issued a “market perform” rating for the company. Wedbush restated an “outperform” rating and issued a $87.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, October 25th. Finally, Needham & Company LLC restated a “buy” rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 26th.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/05/pacira-pharmaceuticals-inc-pcrx-receives-consensus-rating-of-hold-from-brokerages.html.

Pacira Pharmaceuticals (NASDAQ PCRX) opened at $36.10 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 7.84 and a quick ratio of 7.26. Pacira Pharmaceuticals has a 12-month low of $29.81 and a 12-month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.06). Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business had revenue of $70.90 million for the quarter, compared to analyst estimates of $73.37 million. During the same quarter last year, the firm posted $0.21 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. equities research analysts predict that Pacira Pharmaceuticals will post -0.96 earnings per share for the current fiscal year.

In other news, CAO Kristen Marie Williams sold 3,461 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total transaction of $127,191.75. Following the completion of the sale, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at $783,216. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $36.37, for a total value of $1,050,547.45. Following the transaction, the chief executive officer now directly owns 159,164 shares in the company, valued at $5,788,794.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,390 shares of company stock valued at $1,215,480. 6.60% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the stock. Oppenheimer Asset Management Inc. acquired a new position in Pacira Pharmaceuticals during the second quarter valued at $114,000. Benjamin F. Edwards & Company Inc. raised its position in Pacira Pharmaceuticals by 12.2% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after buying an additional 303 shares during the period. Cubist Systematic Strategies LLC raised its position in Pacira Pharmaceuticals by 121.5% during the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after buying an additional 1,752 shares during the period. QS Investors LLC acquired a new position in Pacira Pharmaceuticals during the second quarter valued at $157,000. Finally, Ameritas Investment Partners Inc. raised its position in Pacira Pharmaceuticals by 9.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after buying an additional 302 shares during the period.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.